Marked. - Issue 006
Fresh IP developments from Takeda, Amitiza, Groq, and Groq Health.
Issue No. 006
May 20, 2026
New York
|
|
|
|
|
|
|
|
The IP Briefing · by ESCA Legal
|
|
|
|
| A Boston federal jury found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of Amitiza through an anticompetitive settlement structure. The dispute grew out of earlier patent litigation over the constipation drug and may expose Takeda to trebled damages under federal antitrust law. |
| § | The jury sided with wholesalers, insurers, health funds, and retailers including CVS and Walgreens after a five-week trial. | | § | The case centered on a 2014 settlement involving Takeda, Sucampo Pharmaceuticals, and Par Pharmaceutical after Par sought approval for a generic version of Amitiza. | | § | Purchasers argued the settlement delayed generic competition by six years and forced them to overpay for the drug. | | § | Takeda denies wrongdoing and says it will pursue post-trial motions and an appeal. |
|
| Continue reading → |
| § ESCA Takeaway |
| This issue tracks two different forms of IP risk: a pharmaceutical patent settlement that became antitrust exposure and an AI-era trademark dispute that ended in settlement. |
|
|
| More IP Stories |
|
| § Trademark · Closed |
|
|
| Groq Inc. and Groq Health Inc. resolved a New York federal trademark dispute over the Groq name after litigation that included infringement claims, counterclaims, and summary-judgment motion practice. The settlement closes one branch of a broader set of conflicts around Groq and Grok-based marks in the AI market. |
| § | The case was filed in the Southern District of New York in 2023 under the Lanham Act. | | § | Groq Inc. sued Groq Health Inc. and Florence D. Comite, M.D., alleging trademark infringement tied to the Groq name. | | § | The docket reflects counterclaims and multiple rounds of motion practice before the parties reached a resolution. | | § | The settlement arrives while Groq and Grok-formative marks continue to raise clearance and confusion questions across AI, health, and software markets. |
|
|
Why it matters
Short, high-distinctiveness technology marks can collide quickly when adjacent companies expand into AI, health, and software channels. The settlement is a useful brand-clearance reminder: even a small naming variation can become expensive once a market category gets crowded.
|
| Continue reading → |
|
|
Not subscribed? Sign up for future editions of Marked by ESCA Legal.
|
|
|
|
This newsletter is for informational purposes only and does not constitute legal advice. Published by ESCA Legal. Reading it does not create an attorney-client relationship. Attorney advertising; prior results do not guarantee a similar outcome.
|
|